Treats major depressive disorder. ANDA 78406, held by Aurobindo Pharma. Paroxetine Hydrochloride.
As of Nov 21, 2026, ANDA 78406 (Paroxetine Hydrochloride), held by Aurobindo Pharma, was first approved by FDA on Jul 25, 2007, with 15 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Major Depressive Disorder Paroxetine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of paroxetine in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 25, 2007 | Original application | Approved | None posted |
| Paroxetine HydrochlorideEQ 10MG BASE · tablet;oral | Paroxetine Hydrochloride | Rx |
| Paroxetine HydrochlorideEQ 20MG BASE · tablet;oral | Paroxetine Hydrochloride | Rx |
| Paroxetine HydrochlorideEQ 30MG BASE · tablet;oral | Paroxetine Hydrochloride | Rx |
| Paroxetine HydrochlorideEQ 40MG BASE · tablet;oral | Paroxetine Hydrochloride | Rx |
| Mar 13, 2025 | Supplement 37Labeling · Standard review | Approved | None posted |
| Jan 16, 2024 | Supplement 35Labeling · Standard review | Approved | None posted |
| Jan 19, 2022 | Supplement 31Labeling · Standard review | Approved | None posted |
| Jan 19, 2022 | Supplement 32Labeling · Standard review | Approved | None posted |
| Mar 19, 2020 | Supplement 25Labeling · Standard review | Approved | None posted |
| Mar 19, 2020 | Supplement 27Labeling · Standard review | Approved | None posted |
| Sep 24, 2014 | Supplement 23Labeling · Standard review | Approved | None posted |
| Dec 31, 2013 | Supplement 21Labeling · Standard review | Approved | None posted |
| Jul 31, 2012 | Supplement 17Labeling | Approved | None posted |
| Mar 4, 2011 | Supplement 15Labeling | Approved | None posted |
| Dec 10, 2010 | Supplement 14Labeling | Approved | None posted |
| Jun 15, 2009 | Supplement 3Labeling | Approved | None posted |
| May 6, 2009 | Supplement 6Labeling | Approved | None posted |
| May 6, 2009 | Supplement 9Labeling | Approved | None posted |
| Feb 6, 2008 | Supplement 1Labeling | Approved | None posted |
| Jul 25, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters